Webinars

ARC welcomed Jan Griffin, MD, amyloidosis cardiologist at the Medical University of South Carolina. Dr. Griffin discussed how ATTR affects the heart and explored advances in treatments for ATTR-CM.

She explained the medications currently available, how they work, how doctors know if they’re helping, and what new treatments are coming in the future.

The webinar concluded with a Q&A session.

Original Presentation Date:
June 10, 2025.

Download the Slides →

0:00 — Welcome

3:47 — Introduction

6:07 — ATTR Cardiac Amyloidosis Overview

TTR Stabilizers

10:58 — Vyndamax® / Vyndaqel® (tafamidis)

14:53 — Attruby™ (acoramidis)

TTR Silencers

19:18 — Amvuttra® (vutrisiran)

22:31 — Eplontersen

Gene Editing

25:14 — Nex-z (NTLA-2001)

29:44 — MAGNITUDE Study

Depleting TTR

31:54 — ALXN2220 (NI006)

36:08 — Coramitug (NNC6019/PRX004)

Prevention

37:55 — ACT-EARLY Trial

39:42 — Summary of ATTR Cardiac Therapies

40:53 — Combination Therapy

45:50 — How to Choose Initial Therapy

49:16 — Adjunctive Therapies for Heart Failure

53:52 — ARC Summary of Approved Treatments for ATTR-CM

54:47 — Q&A Session

55:03 — If I’m on one treatment, how should I go about considering other treatments?

57:36 — How often is Amvuttra® (vutrisiran) administered?

57:57 — How does Vitamin A function with reduced TTR?

59:21 — Where and how can I access gene editing treatments?

1:01:00 — When might some of the treatments currently under investigation become available?

1:03:01 — How frequently should I have my biomarkers and medical imaging monitored?

1:04:51 — What are the side effects/risks of taking tafamidis?

1:05:53 — Conclusion

Contact ARC:

Call +1 (617) 467-5170

Email ARC at support@arci.org